Cullinan Oncology
CGEM
113 hedge funds and large institutions have $385M invested in Cullinan Oncology in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 14 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
12% more capital invested
Capital invested by funds: $344M → $385M (+$41M)
7% more funds holding
Funds holding: 106 → 113 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.62% less ownership
Funds ownership: 88.93% → 88.31% (-0.62%)
12% less call options, than puts
Call options by funds: $97K | Put options by funds: $110K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$30.3M |
| 2 |
Morgan Stanley
New York
|
+$13.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.79M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.46M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$9.72M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$5.92M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.51M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.92M |
CGEM Hedge Fund Activity: Q4 2023 in Review
113 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q4 2023, worth a combined $385M — up 12% from $344M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CGEM positions and 14 closed out — a net gain of 9 holders — while 45 added to existing stakes and 24 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $30.3M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.4M sold.
- 113 institutional investors held Cullinan Oncology (CGEM) as of Q4 2023, up from 106 in Q3 2023.
- Funds reported $385M of Cullinan Oncology stock for Q4 2023, up 12% quarter-over-quarter.
- 23 funds opened new Cullinan Oncology positions in Q4 2023 and 14 closed out, a net change of +9 holders.
- The largest Cullinan Oncology buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $30.3M added.
- The largest Cullinan Oncology seller in Q4 2023 was Adage Capital Partners, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2023.